Video Experimental Relacionado
Updated: Sep 9, 2025
07:06
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
27.2K
Un caso de colitis isquémica después de la administración de Baloxavir Marboxil
1Department of Endoscopy, Tanaka Clinic, Japan.
Internal medicine (Tokyo, Japan)
|September 3, 2025
Resumen
Baloxavir marboxil, un tratamiento para la influenza A, puede causar colitis isquémica. Un estudio de caso encontró que un paciente desarrolló síntomas de colitis después de tomar el medicamento, destacando un posible evento adverso.
Área de la Ciencia:
- Gastroenterología
- Enfermedades infecciosas
- Farmacología
Sus antecedentes:
- La gripe A es una enfermedad respiratoria común.
- Baloxavir marboxil es un medicamento antiviral utilizado para el tratamiento de la gripe A.
- Las reacciones adversas pueden ocurrir con cualquier medicamento.
Objetivo del estudio:
- Informar de un caso de colitis isquémica potencialmente asociado con baloxavir marboxil.
- Aumentar la conciencia entre los médicos sobre este posible evento adverso.
Principales métodos:
- Un informe de caso de una mujer de unos 60 años tratada con baloxavir marboxil para la influenza A.
- Se documentaron la presentación clínica, los hallazgos de la colonoscopia y el examen histopatológico.
- Se registraron el tratamiento del paciente y el resultado.
Principales resultados:
- El paciente desarrolló dolor abdominal, diarrea y hematoquecia dos días después de la administración de baloxavir marboxil.
- La colonoscopia reveló edema de la mucosa del colon sigmoide y ulceraciones longitudinales.
- La histopatología confirmó colitis isquémica.
- Los síntomas mejoraron con el tratamiento conservador.
Conclusiones:
- La colitis isquémica es un evento adverso potencial asociado con baloxavir marboxil.
- Los médicos deben considerar esta posibilidad en pacientes que presentan síntomas gastrointestinales después de tomar el medicamento.
Videos de Conceptos Relacionados
01:29Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
316
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
316
01:17Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
01:29Inflammatory Bowel Disease IV: Pharmacological Management
185
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
185
01:17Chronic Bowel Disorders: Introduction
540
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
540
01:21Drugs for Treatment of Constipation-Predominant IBS
326
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
326